Overview

This trial is active, not recruiting.

Condition chronic obstructive pulmonary disease
Treatment no specific intervention for this study
Sponsor Laval University
Collaborator Canadian Institutes of Health Research (CIHR)
Start date September 2011
End date September 2017
Trial size 36 participants
Trial identifier NCT02284932, COPD-20739

Summary

Limb muscle dysfunction, characterized by atrophy and weakness, is amongst the most troublesome systemic consequences of chronic obstructive pulmonary disease (COPD) leading to poor functional status and premature mortality.

One prevailing hypothesis stipulates that the deterioration in muscle structure and function during COPD results from a spillover of inflammatory mediators from the lungs to the systemic circulation and then to the muscles.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
Group : COPD patients No specific intervention for this study
no specific intervention for this study
No specific intervention for this study
Group : healthy volunteers No specific intervention for this study
no specific intervention for this study
No specific intervention for this study

Primary Outcomes

Measure
Decrease of protein degradation in muscles of wasted COPD patients
time frame: At baseline (COPD in a stable state of the disease)

Secondary Outcomes

Measure
Increase of protein synthesis in muscles of wasted COPD patients
time frame: At baseline (COPD in a stable state of the disease)

Eligibility Criteria

Male participants from 55 years up to 75 years old.

Inclusion Criteria: - male - COPD with an FEV1 of under 60% of predicted - non-smoker - between 55 and 75 years old Exclusion Criteria: - all inflammatory disease (HIV, cancer, renal and cardiac deficiency) - hormonal dysregulation - inferior limb pathology - neuromuscular pathology - history of tobacco or alcool abuse - oxygen dependent - recent exacerbation (2 months) of the symptoms of COPD

Additional Information

Official title Muscle Atrophy In Patients With Chronic Obstructive Pulmonary Disease
Principal investigator François Maltais, MD, PhD
Description The investigators objective is to investigate the impact of COPD on key signaling pathways involved in the muscle atrophy. Moderate to severe COPD patients (FEV1 under 60% of predicted) and healthy controls will be recruited. All of the investigators patients will undergo a thorough baseline assessment in pulmonary capacity, muscle force and body composition. Blood sampling and biopsy of the quadriceps will be done. Key proteins of signaling intramuscular pathways involved in protein synthesis and degradation will be measured in the quadriceps.
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Laval University.